PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

doi:10.1007/s00428-013-1500-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Virchows Archiv : an international journal of pathology - 1 Jan 2014

Cuorvo Lucia Veronica, Verderio Paolo, Ciniselli Chiara Maura, Girlando Salvatore, Decarli Nicola, Leonardi Elena, Ferro Antonella, Caldara Alessia, Triolo Renza, Eccher Claudio, Cantaloni Chiara, Mauri Francesco, Seckl Michael, Volante Marco, Buttitta Fiamma, Marchetti Antonio, Silvia Quattrone, Galligioni Enzo, Palma Paolo Dalla, Barbareschi Mattia

Abstract excerpt

PI3K/AKT/mTOR pathway alterations are frequent in patients with infiltrating breast cancer (IBC). Their clinical and pathological relevance has been insufficiently documented. We evaluated PI3KCA for mutations and the expression of PTEN, AKT, mTOR and p70S6K by immunohistochemistry in 246 IBC patients treated with hormone therapy (median follow-up, 97 months). A PI3KCA mutation was observed in 50 out of 229...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Share to Prognosis

Share to Proportional Hazards Models

Share to PTEN Phosphohydrolase

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed

Identifiers

PMID: 24233241
DOI: 10.1007/s00428-013-1500-7

Genes

PTEN
MIB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.PMID 24233241Read ↗

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.Semantic proximity Read ↗

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.Semantic proximity Read ↗

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Semantic proximity Read ↗

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitorsSemantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancerSemantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Semantic proximity Read ↗

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Semantic proximity Read ↗

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.Semantic proximity Read ↗

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology PerspectiveSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.